Autoimmune Hepatitis Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis
This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.
This is a Phase 2a, multi-center, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate safety, tolerability, and efficacy of zetomipzomib in patients with autoimmune hepatitis (AIH) who have not benefited from standard-of-care treatment, had an incomplete response to ≥3 months of standard-of-care treatment, or had a disease flare after standard of care. Zetomipzomib or placebo will be administered weekly for a 24-week treatment period in addition to standard-of-care (glucocorticoids), followed by a 4-week off-treatment safety follow-up period. Zetomipzomib and placebo will be administered subcutaneously (SC) once weekly. At the end of the 24-week treatment period, eligible patients from both the zetomipzomib- and placebo-treated arms who complete the double-blind treatment period can enroll in the open-label extension period to receive an additional 24 weeks of treatment with zetomipzomib. Primary completion date represents the anticipated completion date of the double-blind portion of the study. Study completion date represents the anticipated completion date of the open-label extension portion of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06020976 -
Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
|
||
| Recruiting |
NCT05476900 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
|
Phase 2 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT06250309 -
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
|
N/A | |
| Recruiting |
NCT01661842 -
Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis
|
Phase 1/Phase 2 | |
| Terminated |
NCT04339621 -
AIH Risk Stratification With Multiparametric MRI
|
||
| Not yet recruiting |
NCT04371718 -
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
|
Phase 2 | |
| Completed |
NCT02239562 -
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS
|
Phase 1 | |
| Completed |
NCT02463331 -
Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis
|
Phase 4 | |
| Not yet recruiting |
NCT06356506 -
A Study on Factors of Biochemical Response in Autoimmune Hepatitis
|
||
| Terminated |
NCT04203875 -
Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
|
Phase 1 | |
| Recruiting |
NCT06078098 -
Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
|
||
| Completed |
NCT00838214 -
Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05810480 -
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
|
||
| Recruiting |
NCT03743272 -
Repeatability and Reproducibility of Multiparametric MRI
|
||
| Completed |
NCT03979053 -
Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
|
||
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Recruiting |
NCT04933292 -
A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT06455280 -
SIPLIZUMAB in AILD and LT
|
Phase 1 | |
| Completed |
NCT05532345 -
Discrimination of DILI and AIH by Artificial Intelligence
|